Tips for searching:
• You have to select a product and type at least 2 words to activate the search
• Use only words that are specific to the information you are looking for
• Avoid typing questions or sentences
Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search for MHRA Yellow card in the Google play or Apple app store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Strattera ® (atomoxetine)
This information is intended for UK registered healthcare professionals only in response to your search for information. For current information for all Lilly products, including Summaries of Product Characteristics, Patient Information Leaflets and Instructions for Use, please visit: www.medicines.org.uk (England, Scotland, Wales) or www.emcmedicines.com/en-GB/northernireland/ (Northern Ireland).
Can patients on Strattera® (atomoxetine) receive a COVID-19 vaccine?
The use of vaccines against SARS-CoV-2 in patients treated with atomoxetine has not been studied.
SARS-CoV-2 vaccination with atomoxetine
The use of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in patients treated with atomoxetine has not been studied by Eli Lilly and Company.
Decisions regarding the use of any vaccination, including SARS-CoV-2 vaccines, in patients treated with atomoxetine should be made at the discretion of the prescribing physician using their best clinical judgment, and must be made by the clinician after careful consideration of the risk factors of the patient as well as the risks and benefits of vaccination.
Date of Last Review: 28 November 2023